I-Mab (IMAB)
After hours:
| Previous Close | 12.06 |
| Open | 11.98 |
| Bid | 11.80 x 800 |
| Ask | 12.60 x 800 |
| Day's Range | 11.98 - 12.66 |
| 52 Week Range | 10.14 - 85.40 |
| Volume | |
| Avg. Volume | 1,297,054 |
| Market Cap | 1.008B |
| Beta (5Y Monthly) | 1.01 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.54 |
| Earnings Date | Mar 29, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 89.52 |
- Simply Wall St.
We're Hopeful That I-Mab (NASDAQ:IMAB) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- Bloomberg
Chinese Biotech I-Mab Weighing Options Including Sale
(Bloomberg) -- Chinese biotechnology firm I-Mab is exploring options including a sale of the business amid takeover interest from other global drugmakers, according to people familiar with the matter.Most Read from BloombergKremlin Insiders Alarmed Over Growing Toll of Putin’s War in UkraineNetflix Rout Is Worst Since 2004, Punishing Roku and Disney, TooAckman Loses More Than $430 Million on 3-Month Netflix BetRussia Test-Fires Nuclear-Capable ICBM in Warning to U.S. AlliesUkrainian Troops Risk
- Bloomberg
Hong Kong SPAC Rush Attracts Olympic Champions to Sofa Moguls
(Bloomberg) -- Hong Kong is finally joining the SPAC bandwagon, and a slew of influential personalities have lined up to lend credibility to the city’s inaugural offerings -- from an Olympic medalist to political power brokers and a sofa tycoon.Most Read from BloombergNever Had Covid? You May Hold Key To Beating the VirusPutin ‘Misinformed’ by Advisers on the War, White House SaysUkraine Update: Talks With Russia May Resume Friday, Kyiv SaysApple and Meta Gave User Data to Hackers Who Used Forge
